Punjab set to recruit 1000 Medical Officers

Chandigarh: In a major boost to the state’s healthcare infrastructure, the Punjab Government has decided to recruit 1,000 Medical Officers (MBBS). The decision was revealed during a meeting held between Principal Secretary Health and Family Welfare Kumar Rahul, Director Health Services Dr. Hitinder Kaur, Director PHSC Dr. Anil Goyal, and representatives of the Punjab Civil Medical Services Association (PCMSA).

Talking to Medical Dialogues, Dr. Akhil Sarin, President of PCMSA, stated, “Notably, this is the largest round of recruitment of medical officers held over the last few decades. PCMSA firmly believes that this move will significantly strengthen the general emergency and specialist services alike at various public healthcare facilities of the state.” “It also showcases the persistent positive engagements between the government and PCMSA over the last couple of years on the issue of regular and time-bound recruitment of Medical Officers, effectively aimed at bolstering the public healthcare services of the state,” he added.

The association was briefed on several key developments following comprehensive discussions among Health Minister Dr. Balbir Singh, Finance Minister Harpal Cheema, and Kumar Rahul. As part of efforts to strengthen security at health institutions, the Finance Department has approved the hiring of security guards through PESCO, an ex-servicemen organisation. Security personnel will be deployed round the clock at all District Hospitals, Sub-Divisional Hospitals, and Community Health Centres offering 24×7 medicolegal services. Morning-hour security coverage will be ensured at the remaining CHCs and Employees’ State Insurance hospitals. The proposal is expected to be formally sent to the Finance Department within the next few days, with approval likely in the next two to three weeks. 

PCMSA has praised the government’s proactive response to the long-pending security concerns and expressed hope that adequate arrangements will be in place within a few weeks. In addition to recruitment and security measures, several administrative reforms were discussed. These include a speaking order on the rationalisation of postgraduate allowance for pre-2016 batches, early clearance of pending Modified Assured Career Progressions (MACPs), issuance of MACP letters for batches from 2020–21 onwards, and finalisation of the postgraduate policy by the end of the month. The letter regarding leave rules for Senior Medical Officers and above ranks has also been reverted, offering further relief to senior personnel.

Medical Dialogues had earlier reported that 2,500 doctors in the state started their agitation on January 20th, urging the government to fulfill its time-bound commitments. This came after talks between the finance department and the PCMSA, but no significant outcomes were achieved. Finally, with the new recruitment, PCMSA acknowledged these initiatives as crucial steps toward strengthening the healthcare delivery system.

Powered by WPeMatico

Aurobindo Pharma arm CuraTeQ Biologics gets positive opinion for breast cancer drug Dazublys from EMA

Hyderabad: CuraTeQ Biologics s.r.o., a wholly owned step-down subsidiary of Aurobindo Pharma Limited, has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending marketing authorisation of Dazublys (150
mg powder for concentrate for solution for infusion), its trastuzumab biosimilar, for the treatment of
HER2-positive metastatic and early breast cancers.


Trastuzumab specifically binds and inhibits the human epidermal growth factor receptor 2 (HER2)
protein, which is over-expressed on certain types of solid cancers such as breast and gastric
cancer. By binding to the extracellular domain of HER2, trastuzumab disrupts its ability to signal,
leading to cell cycle arrest, reduced tumor growth, and potentially immune system activation to
destroy cancer cells.

Commenting on the update, Dr. Satakarni Makkapati, Director of Aurobindo Pharma and CEO Biologics,
Vaccines and Peptides stated, “The CHMP’s positive opinion is based on demonstrating comprehensive
analytical similarity and clinically no meaningful differences between Dazublys and the reference biologic
product Herceptin in terms of pharmacokinetics (PK), pharmacodynamics (PD), efficacy, safety, and
immunogenicity. Upon European Commission approval that is expected in July, Dazublys will be available
for use across EU member states. This marks our third biosimilar to receive CHMP’s endorsement and the
fourth overall in the EU, alongside the approval of Bevqolva (a bevacizumab biosimilar) by the MHRA in
November 2024. Biosimilars are playing an important role in improving cancer care, and we remain
committed to expanding our biosimilars portfolio to address the unmet needs of patients.”

Aurobindo Pharma’s Vice Chairman and Managing Director Mr. Nithyananda Reddy said, “The CHMP’s
positive opinion of a third biosimilar from our portfolio in a five-month time period underscores our
extensive efforts in building biosimilars as one of the core businesses at Aurobindo. By 2030, we are
committed to launching at least 10 biosimilars across oncology and immunology therapy segments,
furthering our mission to serve patients with high-quality, cost-effective therapies.”

CuraTeQ Biologics Private Limited, a subsidiary of Aurobindo Pharma Limited, is a global
biopharmaceutical company headquartered in Hyderabad, India. The company is focused on developing biosimilars for the treatment of various cancers
and autoimmune diseases. CuraTeQ’s pipeline consists of fourteen biosimilars, primarily targeting the
immunology and oncology segments. It has end-to-end capabilities in producing a full range of products
from bulk drug substance to fill-finish and packaged drug products.

Powered by WPeMatico

Bengaluru Doctor accused of throwing stray dog to death from third floor

Bengaluru: A Bengaluru-based doctor has been booked for animal cruelty after allegedly killing a stray dog by throwing it from the third floor of his apartment building in Adugodi on April 22.  

The police have registered an FIR based on a complaint filed by Ayush Bhattacharjee, a student and resident of the apartment complex. The doctor has been charged under Section 325 of the Indian Penal Code, which pertains to mischief committed by killing, poisoning, or rendering an animal useless.

According to the news reports, the doctor, a neurosurgeon, is a resident of Brindavan apartment at Lakkasandra and was reportedly unhappy with the presence of a stray dog named Scooby, which had been taken in and cared for by other residents. The incident allegedly occurred in February 2025, when the doctor is accused of throwing the dog from the third floor of the building. 

The complainant noticed the dog bleeding and writhing in pain and took it to a hospital for treatment. The dog had sustained an injury to the spinal cord and was under treatment for two months. After recovery, the dog was brought back to the apartment and placed under the residents’ care.

However, on April 20, a disturbing incident occurred when the residents heard a loud sound. Upon checking, they found that the dog had fallen onto a car parked on the roadside, damaging its windshield. The car owner subsequently filed a complaint against the doctor for the damage to his property.

Also Read: Amritsar based doctor leaves pet dogs home alone for 6 months without food, booked

As per the recent media reports by The Hindu, some residents of the apartment allegedly noticed Dr. Ballal going inside his apartment and slamming the door shut. Some residents went to question him while others rushed the dog to a hospital, where the animal succumbed to its injuries.

Further investigation into the doctor’s background revealed a potentially alarming pattern. In 2022, while pursuing his PG in surgery in Indore, Madhya Pradesh, the doctor was allegedly involved in the death of another stray dog. The incident occurred on August 7, 2022, and was brought to the attention of the police by an NGO, People for Animals, after CCTV footage showed Dr. Ballal grabbing a dog by the neck.

Also Read: Viral Video: Jodhpur Plastic Surgeon booked for dragging dog along road

According to TNIE, the Madhya Pradesh High Court, however, quashed the FIR against him on April 26, 2024, on the grounds that the FIR was filed only on the basis of apprehension and “not on the basis of any concrete evidence”.

The Adugodi police have registered an FIR and stated that they will summon the doctor for questioning.

Powered by WPeMatico

Orissa HC imposes Rs 10,000 fine on doctor for false claim of Padma Shri award

Cuttack: Observing that the writ petition unnecessarily wasted valuable time of the court, the Orissa High Court dismissed a petition filed by a doctor, also a writer who claimed that he was unfairly denied the country’s fourth highest civilian honour- Padma Shri Award in the field of literature and imposed a fine of Rs 10,000 for wasting the court’s time. 

The petitioner claimed that another person with the same name from Dhenkanal district falsely claimed to be the Padmashri Awardee, which was meant to be his award, as his name was included in the Padma Shri awardee list declared on January 25, 2023. 

He told the court that he had received a phone call from the Ministry of Home Affairs informing him about his selection for the award. He also said he had written 29 books in Odia and deserved the recognition, while the other person, who is a journalist, had not written any books.

Also read- Padma Awards in Medicine 2025: Here are this year’s Padma Vibhusan, Padma Bhushan, Padma Shri recipients

However, the court found that Mishra failed to provide any proof showing he was selected for the award. Despite being given time, he could not submit any official documents or confirmation.

Single bench of Justice S.K. Panigrahi observed, “Considering the facts and submissions made, this Court is of the view that the Petitioner has approached this Court on the basis of some phone calls from somebody stating that he is the recipient of the “Padmashri Award” for the year 2023 in the field of Literature. Despite a few adjournments were granted to the Petitioner to place on record all the documents which embolden his claim, the Petitioner has failed to submit any document where his name has been figured as a “Padmashri Awardee”. This shows that the Petitioner has unnecessarily created controversy and also demeaned the prestige of the award and tried to malign the image of the Opposite Party No.2.” 

Dismissing the petition, the court imposed a fine of Rs 10,000 on the petitioner and asked him to pay the amount to the Orissa High Court Bar Association, Cuttack within a period of 10 days. The money will be used for purchasing books by the Bar.

“In such view of the matter, this Court deems it appropriate to impose a cost of Rs.10,000/- (Rupees Ten Thousand Only) on the Petitioner for unnecessarily wasting the valuable time of this Court. The same shall be paid to the Orissa High Court Bar Association, Cuttack for purchasing of books within a period of ten days from today,” concluded the court. 

To view the official order, click on the link below:

Also read- Renowned Gynaecologist, AIIMS Former HOD, Dr Neerja Bhatla conferred with Padma Shri

Powered by WPeMatico

Centre launches National Zero Measles-Rubella Elimination campaign targeting 2026 goal

New Delhi: Union Minister of Health and Family Welfare, Shri Jagat Prakash Nadda, recently virtually launched the National Zero Measles-Rubella Elimination campaign 2025-26 on the first day of the World Immunization Week (24-30 April), marking a significant step towards India’s goal of eliminating Measles and Rubella by 2026.

On the occasion, Union Health Minister released multi-language M-R IEC materials (posters, radio jingles, MR elimination and official U-WIN launch film) for creating awareness in the communities. These IEC materials were also shared with all States/UTs for adaptation and rollout during the MR Elimination Campaign 2025-26.

Addressing the occasion, Shri JP Nadda stated that, “Today is momentous occasion as the launch of Measles-Rubella elimination campaign 2025-26 marks an opportunity to achieve 100% immunization coverage to provide high quality lifestyle to children by administering them with the two doses of Measles and Rubella vaccine.” Noting that this disease is of a highly contagious nature that hampers not only children’s life but also cause misery to their parents, Shri Nadda underlined the importance of ensuring that not even a single child is left behind.

Also Read:Fatty liver is preventable, reversible through healthy lifestyle and food habits: JP Nadda

The Union Health Minister congratulated the Ministry for getting recognition with the prestigious Measles and Rubella Champion Award by the Measles and Rubella Partnership in 2024. He highlighted that “332 districts in the country have reported zero measles cases and 487 districts have reported zero rubella cases during January- March 2025 which underscores the progress achieved in the goal of M-R elimination.”

Shri Nadda highlighted the need for keeping the IDSP activated and strengthening surveillance. “We have to target the elimination of M-R in the same way as Polio and Maternal and Neonatal Tetanus elimination was achieved”, he stated. He urged the states and UTs to be attentive, alert, and proactive and work with a ‘ACT NOW’ policy.

Shri Nadda also urged the State Ministers and Chief Medical Officers to hold public and press meetings where people at large can be informed about the vaccination drive through active Jan Bhagidari. He also called upon States for an inclusive participation of all MLAs, MPs, local and Panchayat heads to spread awareness about the vaccination against Measles and Rubella. He also urged the frontline workers to reach out to remote and hard to reach areas, slums, migratory population, areas with frequent outbreaks. “We have to reach out to people in the last mile to ensure that we achieve 100% coverage”, he stated. He also emphasized on the need for coordinating with line ministries. He concluded his address by stating that “if we work and act from today, we will be able to achieve success tomorrow.”

Background:

Measles and Rubella are highly infectious viral diseases that can lead to serious illnesses, lifelong complications, and even death. Due to their high infection rate, India has set a goal to eliminate these diseases by 2026. Under the Universal Immunization Programme (UIP), two doses of the Measles-Rubella (MR) vaccine are provided free of cost to all eligible children, at 9-12 months and 16-24 months of age, respectively. Currently, India’s MR vaccination coverage stands at 93.7% for the first dose (2024-25 HMIS data) and 92.2% for the second dose.

In 2024, India has recorded a remarkable decline of 73% in Measles cases and a 17% reduction in Rubella cases in comparison with 2023.

India’s plan for eliminating measles and rubella includes a comprehensive framework:

Immunization: Achieve and maintain high population immunity with > 95% vaccination coverage with 2 doses of measles and rubella containing vaccines in each district of the country.

Surveillance: Sustain a sensitive and timely case-based surveillance system for measles & rubella.

Outbreaks: Ensure adequate preparedness and timely response to measles and rubella outbreaks.

Linkages: Strengthen support and linkages to achieve the above strategic objectives.

Demand Generation for Vaccination: Focused mass awareness campaigns to mitigate the risks of non-vaccination and dispel myths related to MR vaccine for addressing vaccine hesitancy and increasing coverage.

In recognition of country’s exceptional efforts in prevention of Measles and Rubella, India was awarded the prestigious Measles and Rubella Champion Award by the Measles and Rubella Partnership at the American Red Cross Headquarters in Washington D.C. on March 6, 2024.

Under the Universal Immunization Programme (UIP), India runs world’s largest vaccination programme for pregnant women and children – reaching out to 2.9 crore pregnant women and 2.6 crore newborns annually. This provides protection against 12 vaccine preventable diseases (VPDs) such as Polio, Measles, Rubella, Diphtheria, Tetanus, Rotavirus diarrhoea, Hepatitis B among others. U-WIN digital platform for vaccination, launched by the Hon’ble Prime Minister is being utilized extensively to record vaccination events, generate vaccination certificate and book appointment for vaccination across the country.

India’s Universal Immunization Programme, has been instrumental in reducing mortality rates and controlling infectious diseases among children under five years of age. From 2014 to 2020, under-5 mortality rates dropped from 45 to 32 per 1,000 live births (Sample Registration System – 2020). Since 2014, under UIP, over 6 new vaccines have been introduced including MR vaccine.

Smt. Punya Salila Srivastava, Union Health Secretary; Dr Rajiv Bahl, Secretary, Dept. of Health Research and DG, ICMR; Smt. Aradhana Patnaik, Addl. Secretary and Mission Director (NHM), Union Health Ministry; Smt. Meera Srivastava, Joint Secretary, Union Health Ministry, Additional Commissioner (Immunization), Additional Chief Secretaries, Principal Secretaries (Health), Mission Directors (NHM) and State Immunization Officers from States/UTs had joined the virtual launch event.

Also Read:Union Health Minister JP Nadda launches Ayushman Bharat scheme in Odisha

Powered by WPeMatico

KNRUHS Notifies for Round 2 MPH Counselling, Details

Telangana- Through a notification, Kaloji Narayan Rao University of Health Sciences (KNRUHS) has notified regarding the conduction of the second phase counselling for allotment of vacant seats of the MPH course after the first phase of counselling under Competent Authority Quota (CQ) and Management Quota (MQ) in the affiliated colleges.

As per the notification, the Verification of original certificates and exercising options manually for the second phase of counselling for provisional admission into the MPH course under Competent Authority Quota and Management Quota in colleges affiliated to KNRUHS in the State of Telangana for the Academic year 2024-25 will be held on 28 April 2025, 10.00 AM to 12.00 Noon at Directorate of Admissions, Kakatiya University, Warangal.

INSTRUCTIONS TO THE CANDIDATES

1 Candidates who had attended the certificate verification and are made eligible for counselling need not attend the verification. However, the candidates who were allotted seats in the first phase of counselling and are interested in sliding to another college/quota (from CQ to MQ & vice-versa) can report at the verification centre and exercise options.

2 Candidates who haven’t reported to the allotted college are also eligible to exercise options in the second phase of counselling.

The candidates who have to attend counselling shall submit all original certificates for verification and also submit one set of self-attested Xerox copies.

FEES

S.NO

CATEGORY

UNIVERSITY FEE

1

CQ

₹ 17,700/-

2

MQ

₹ 22,700/-

3

Foreign Nationals

₹ 27,700/-

DOCUMENTS

i Hall Ticket of Entrance Test.

ii Original Degree of the qualifying exam.

iii First to final year marks memos.

iv Study certificate of Degree course.

v Study certificates from VI to Intermediate.

vi Date of birth proof (SSC Memo).

vii Latest Category/Community Certificate issued by Competent Authority.

viii Any other certificates as per regulations.

The notification further informed that after the completion of certificate verification, the eligible candidates shall exercise options for admission into the MPH course for the AY 2024-25. The option form will be provided by the verification officer. Candidates should exercise options in the options forms provided and submit the same to the verification officer.

To view the notification, click the link below

https://medicaldialogues.in/pdf_upload/knruhs-notifies-for-second-phase-mph-counselling-for-ay-2024-25-details-284413.pdf

Powered by WPeMatico

Elevated TyG-BMI may Predict Mortality in Critically Ill Ischemic Stroke Patients: Study

A new study published in the journal of BMC Cardiovascular Diabetology showed that in patients with critically sick ischemic stroke (IS), increased triglyceride glucose-body mass index (TyG-BMI) is substantially linked to an increased risk of short-term all-cause mortality.

Focal neurological dysfunction and cerebral tissue necrosis are hallmarks of ischemic stroke, which is usually caused by insitu thrombotic events or the embolization of atherothrombos from proximal artery sources. Moreover, the most frequent causes of ischemic stroke attributable to other causes include hematological illnesses, such as essential thrombocythemia, polycythemia vera, and thrombotic thrombocytopenic purpura, which can also present as acute ischemic stroke.

Calculated by multiplying fasting triglyceride and fasting glucose levels, the triglyceride-glucose index is a simple and accurate surrogate diagnostic for evaluating insulin resistance (IR), which is associated with IS. In order to fill up current research gaps and provide more accurate biomarker references for therapeutic applications, this study, which is based on the eICU database, examines the connection between the TyG-BMI and 28-day mortality in critically ill IS patients.

The effects of the TyG-BMI on 28-day hospital and intensive care unit mortality were examined using multivariate Cox regression models. To investigate the nonlinear association between the TyG-BMI and 28-day mortality, restricted cubic splines (RCS) were used. K-M curves were used to compare the results of the various TyG-BMI groups. Furthermore, subgroup and interaction analyses were conducted to confirm the results’ resilience.

The mean age of the 1,362 severely sick IS patients that were included was 68.41 ± 14.16 years, and 47.50% of them were male. The high TyG-BMI group had substantially greater ICU and 28-day hospital mortality, according to multivariate Cox regression analysis. The TyG-BMI and 28-day inpatient mortality had a nonlinear positive connection, according to RCS analysis.

There was a 37.3% rise in 28-day hospital mortality for every 1 standard deviation (SD) increase in TyG-BMI below the inflection point of TyG-BMI = 380.37, and an 87.9% decrease in 28-day hospital mortality for every 1 SD increase in TyG-BMI beyond 380.376. The P value for the log-likelihood ratio test is 0.004. The TyG-BMI showed a strong positive linear connection in RCS for 28-day ICU mortality. Overall, among critically sick IS patients in the US, an elevated TyG-BMI is substantially associated with a higher risk of short-term all-cause mortality. 

Reference:

Ouyang, Q., Xu, L., & Yu, M. (2025). Associations of triglyceride glucose-body mass index with short-term mortality in critically ill patients with ischemic stroke. Cardiovascular Diabetology, 24(1). https://doi.org/10.1186/s12933-025-02583-1

Powered by WPeMatico

Glucosamine Use Linked to Lower Risk of Diabetic Nephropathy: Study

According to a study published in Nutrition & Diabetes, regular use of glucosamine, a supplement often taken for joint pain, may reduce the risk of microvascular complications, including diabetic nephropathy, in individuals with type 2 diabetes. The findings, based on UK Biobank data, are promising but limited by the study’s observational design and lack of detailed dosage information.

Glucosamine is a widely used supplement for treating osteoarthritis and joint pain. New evidence suggests a potential association between glucosamine and type 2 diabetes, inflammation and cardiometabolic risk. We aimed to prospectively evaluate the association of habitual glucosamine use with risk of diabetic microvascular complications based on data from the large-scale nationwide prospective UK Biobank cohort study.

This analysis included 21,171 participants with type 2 diabetes who were free of microvascular complications from the UK Biobank. Incidence of diabetic microvascular complications was ascertained via electronic health records. The Cox proportional hazards model was used to assess the relationship between glucosamine use and the risk of diabetic microvascular complications. Subgroup analyses and sensitivity analyses were performed to explore the potential effect modifications and the robustness of the main findings.

Results: At baseline, 14.5% of the participants reported habitual use of glucosamine supplements. During a median follow-up of 12.3 years, 4399 people developed diabetic microvascular complications, including 2084 cases of incident diabetic nephropathy, 2401 incident diabetic retinopathy, and 831 incident diabetic neuropathy. Glucosamine use was significantly associated with lower risks of composite microvascular complications (hazard ratio (HR) 0.89, 95% CI: 0.81 to 0.97) and diabetic nephropathy (HR 0.87, 95% CI: 0.76 to 0.98) in fully adjusted models.

However, there was no significant inverse association between glucosamine use and the risk of diabetic retinopathy (HR 0.94, 95% CI: 0.83 to 1.06) or diabetic neuropathy (HR 0.88, 95% CI: 0.71 to 1.08). Habitual use of glucosamine supplement was significantly associated with lower risks of composite microvascular complications and diabetic nephropathy but not retinopathy or neuropathy in individuals with type 2 diabetes.

Reference:

Cheng, ZJ., Luo, Yf., Zhu, Qy. et al. Association of habitual glucosamine use with risk of microvascular complications among individuals with type 2 diabetes: a prospective cohort study in UK biobank. Nutr. Diabetes 15, 12 (2025). https://doi.org/10.1038/s41387-025-00369-8

Powered by WPeMatico

UTHealth Houston research unveils Link between circadian rhythm and heart attack severity

The molecular mechanism behind why heart attacks can vary in severity depending on the time of day has been uncovered by researchers at UTHealth Houston, potentially paving the way for innovative treatments that align with the natural circadian rhythm.

The study’s findings were published in Nature.

Previous research has shown that the severity of heart damage after an acute myocardial infarction, or heart attack, varies depending on the time of day, with morning attacks resulting in more significant damage and worse outcomes. However, the reasons behind these variations have remained unclear.

“If you have a heart attack in the morning, you are more likely to have fatal arrhythmias, heart failure, and you’re more likely to die from it. The question we asked is ‘Why?’” said Holger Eltzschig, MD, PhD, senior author, and chair and professor of the Department of Anesthesiology, Critical Care and Pain Medicine at McGovern Medical School at UTHealth Houston.

Researchers identified an interaction between two proteins, BMAL1 and HIF2A, as the key factor underlying time-of-day differences in the severity of heart injury following a heart attack. BMAL1 is a core circadian rhythm protein, responsible for regulating biological processes like sleep-wake cycles, metabolism, and hormone release. HIF2A helps the body adapt to hypoxia — low oxygen levels — by stimulating red blood cell production, promoting the growth of new blood vessels, and enhancing cell survival under low-oxygen conditions.

Heart attacks occur when blood flow to the heart is blocked and the muscle begins to die from lack of oxygen. Researchers discovered this interaction between BMAL1 and HIF2A regulated how heart cells in mice responded to low oxygen levels after a heart attack, modulating the heart’s response to injury.

In the preclinical study, researchers found that heart attacks that occurred around 3 a.m. resulted in greater damage to the heart, including larger infarct size and increased risk of heart failure. Heart attacks that occurred at 3 p.m. were less severe, and the heart was better able to adapt to low oxygen levels and promote efficient healing.

The research also revealed that the proteins BMAL1 and HIF2A target a specific gene, amphiregulin (AREG), which plays a vital role in regulating the extent of heart damage throughout the day. By targeting the BMAL1 and HIF2A-AREG pathway with drugs, researchers found they could provide significant protection to the heart, especially when treatments were timed to align with the body’s circadian phase.

According to Eltzschig, future clinical trials must evaluate whether aligning treatments with the body’s internal clock can enhance patient outcomes.

“This discovery opens up new avenues for treating heart attacks by considering the timing of drug administration,” said Eltzschig, who is John P. and Kathrine G. McGovern Distinguished University Chair at McGovern Medical School. “Our findings highlight the potential to use targeted drugs toward those proteins to reduce the severity of heart attacks when administered at specific times. Similarly, patients undergoing cardiac surgery may benefit from such drugs, like the hypoxia-inducible factor activator vadadustat, when given before their operation.”

The research team included Kuang-Lei Tsai, PhD, assistant professor, and Tao Li, PhD, a postdoctoral researcher and co-first author, from the Department of Biochemistry and Molecular Biology at McGovern Medical School. Using high-resolution cryo-electron microscopy, they were able to reveal the detailed structural interactions between BMAL1 and HIF2A to support future drug development targeting the BMAL1-HIF2A complex. This work provided the first direct molecular evidence of their complex formation and offered critical insights that could guide the development of new therapeutic strategies, Eltzschig said.

Reference:

Ruan, W., Li, T., Bang, I.H. et al. BMAL1–HIF2A heterodimer modulates circadian variations of myocardial injury. Nature (2025). https://doi.org/10.1038/s41586-025-08898-z

Powered by WPeMatico

Study: Antibiotic exposure before age two linked to childhood obesity

Taking antibiotics within the first two years of life is linked to a higher body mass index (BMI) in childhood, according to a new study. The research will be presented at the Pediatric Academic Societies (PAS) 2025 Meeting, held April 24-28 in Honolulu.

Researchers found that children exposed to antibiotics in the first two years of life had a 0.067 higher BMI adjusted for age and sex, a 9% greater risk to be overweight, and a 20% greater risk to be obese than children who were unexposed.

Researchers found no correlation between BMI and antibiotic use before pregnancy, during pregnancy, or at birth.

Antibiotics prescribed to young children are prevalent, according to researchers. The majority of children are prescribed antibiotics within the first two years of life. Approximately one-fourth of children are exposed to antibiotics during pregnancy and one-third during vaginal birth.

“Antibiotic exposure in the first two years of life has a stronger association with childhood weight gain than exposure during pregnancy stages or other early ages,” said Sofia Ainonen, MD, PhD, medical doctor at the University of Oulu in Finland and presenting author. “Providers need to be cautious about prescribing antibiotics for young toddlers, especially unnecessary antibiotics for upper respiratory tract infections.”

Childhood obesity is an increasing challenge worldwide, with over 159 million school-aged children diagnosed with obesity in 2022.

The study followed 33,095 vaginally born children in Finland to see if antibiotics before pregnancy, during the perinatal period, and after pregnancy was associated with higher BMI at age two and age 12.

Powered by WPeMatico